Oct 28, 2015 at 20:15 | Source: PTI
As per the information available on the USFDA website, Ohm Laboratories Inc, a unit of Ranbaxy Laboratories, which the company acquired last year, is recalling 10,85,095 boxes for being "Superpotent Drug: Out Of Specification".
Oct 11, 2015 at 11:27 | Source: PTI
The government is likely to commission a study soon to assess the impact of foreign direct investment in existing pharmaceutical companies in view of concerns expressed on the issue by a Parliamentary panel.
Oct 09, 2015 at 08:36 | Source: Moneycontrol.com
Sun Pharmaceutical Industries Ltd has informed BSE that the Company has withdrawn its appeal in the lawsuit filed by erstwhile Ranbaxy Laboratories Limited (Ranbaxy) in November 2014 in a US District Court against U.S. Food and Drug Administration (FDA).
Sep 24, 2015 at 16:42 | Source: CNBC-TV18
Prakash Diwan of prakashdiwan.in is of the view that Lupin may test Rs 2600-2700.
Sep 24, 2015 at 13:25 | Source: CNBC-TV18
Deepak Shenoy of capitalmind.in has a positive stance on Sun Pharmaceutical Industries and Strides Arcolab.
Sep 24, 2015 at 11:30 | Source: CNBC-TV18
Watch the interview of Deepak Shenoy of capitalmind.in with Latha Venkatesh and Ekta Batra on CNBC-TV18, in which he shared his readings and outlook on the market, specific stocks and sectors.
Sep 23, 2015 at 14:11 | Source: PTI
Shivinder Mohan Singh (40), who is the co-founder of the healthcare chain will become the Non-Executive Vice-Chairman with effect from January 1, 2016, the company said in a statement.
Sep 21, 2015 at 12:45 | Source: Moneycontrol.com
Sun Pharmaceutical Industries and Strides Arcolab have entered into a definitive agreement to acquire erstwhile Ranbaxys Solus and Solus Care for Rs 165 crore.
Sep 21, 2015 at 08:43 | Source: CNBC-TV18
Stocks in news are: Sun Pharmaceutical Industries, Ranbaxy Laboratories, Strides Arcolab, IDBI Bank, Axis Bank, IDFC, SKS Microfinance, Hotel Leela Venture, Ashok Leyland, Asian Paints, Lupin, Tilaknagar Industries.
Sep 19, 2015 at 15:18 | Source: PTI
Sun Pharma and Strides have entered into a definitive agreement related to erstwhile Ranbaxy's 'Solus' and 'Solus Care' divisions operating in the central nervous system (CNS) segment in India, the company said in a statement.